Social vulnerability and use of postpartum long-acting reversible contraception and sterilization - 29/06/22
Plan
M.H.M. reports serving as a paid consultant for RAND Corporation and the Society of Family Planning. A.F.P. reports serving as a consultant for Maven Clinic. The remaining authors report no conflict of interest. |
|
M.H.M., A.F.P., D.M.M., D.Z., and G.E.K. are financially supported by a contract from Blue Cross Blue Shield of Michigan for their roles in the Michigan Women’s Health Initiative. The opinions, beliefs, and viewpoints expressed by the authors do not necessarily reflect those of Blue Cross Blue Shield of Michigan or any of its employees. M.H.M. reports receiving extramural support from the Agency for Healthcare Research and Quality, United States under grant number K08 HS025465. |
Vol 227 - N° 1
P. 111 - juillet 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?